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Abstract
Toxins could be effective anti-cancer drugs, if their selective delivery into cancer cells could be
achieved. We have shown that the energy of membrane associated-folding of water-soluble
membrane peptides of pHLIP® (pH Low Insertion Peptide) family could be used to move cell-
impermeable cargoes across the lipid bilayer in cytoplasm of cancer cells. Here we present the
results of a study of pHLIP-mediated cellular delivery of a polar cell-impermeable toxin, α-
amanitin, inhibitor of RNA polymerase II. We show that pHLIP can deliver α-amanitin into cells
in a pH-dependent fashion and induce cell death within 48 hours. Translocation capability could
be tuned by conjugating amanitin to the C-terminus of pHLIP via linkers of different
hydrophobicity cleavable in cytoplasm. pHLIP-SPDP-amanitin, which exhibits 4–5 times higher
anti-proliferative ability at pH 6 compare to pH 7.4, was selected as the best construct. The major
mechanism of amanitin delivery is direct translocation (flip) across a membrane by pHLIP and
cleavage of S-S bond in a cytoplasm. Anti-proliferative effect was monitored on four different
human cancer cell lines. pHLIP-mediated cytoplasmic delivery of amanitin could open great
opportunities to use the toxin as a potent pH-selective anti-cancer agent, which predominantly
targets highly-proliferative cancer cells with low extracellular pH.
INTRODUCTION
One of the main goals of cancer treatment is to kill cancer cells without affecting cells in
healthy tissues and organs. A number of toxic compounds have been tested; however, the
side effects were significant. Therefore therapeutic use of these compounds is limited unless
they would be delivered specifically to cancer cells. If the target of a polar therapeutic is
cytoplasmic, the selective delivery of therapeutics to a tumor is not sufficient to improve
treatment; it is necessary to move the drug molecule across cellular membrane and release it
inside the cell. During the last decades various nanocarriers had been introduced for
encapsulation of therapeutic payloads and delivery to tumors if tumor targeting molecules
decorate nanocarriers (1, 2). The mechanism of cellular entry of nanocarriers is
predominantly endocytotic, which leads to the trapping of therapeutic molecules in
endosomes. pH-sensitive functionalities could be incorporated into nanocarriers to promote
disruption of endosomal membranes and facilitate payload release into the cytoplasm (3–7).
We are developing a new approach for direct cytoplasmic delivery of polar cargo. Our
concept is based on utilization of the energy of membrane-associated folding of family of
pHLIPs (pH Low Insertion Peptides) for the pH-dependent translocation of cell-
impermeable molecules across plasma membrane into the cytoplasm (8). We demonstrate
targeting of acidic solid tumors by pHLIP peptides labeled with fluorescent, PET and
SPECT imaging agents, delivery of gold nanoparticles and liposomes to acidic diseased
tissue, and cytoplasmic delivery of various cell-impermeable molecules (9–16). Among
functional cargo molecules tested for intracellular delivery by pHLIP were bi-cyclic hepta-
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peptides, mushroom phallotoxins (8, 17). The toxins were translocated into cultured cells in
a pH-dependent manner, released into the cytoplasm by cleavage of S-S bond, and bound to
intracellular target, F-actin. Phallatoxins delivered to cells by pHLIP induced stabilization of
cell cytoskeleton, which led to cell death. We show that hydrophobicity of phallotoxin cargo
could be tuned to enhance translocation (18). The objective of current study is an evaluation
of pHLIP capability of translocating another mushroom toxin, bi-cyclic octa-peptide, α-
amanitin. Despite the similarity in chemical structure between phallo and amanita toxins,
they possess very different biological activity (19–21). Amanitin is an inhibitor of RNA
polymerase II, inhibition of which blocks protein synthesis and induces cell death (22). This
toxin could be considered as a potent anti-cancer drug if it could be specifically delivered to
the cytoplasm of cancer cells. Here we demonstrate that pHLIP can deliver α-amanitin into
cells in a pH-dependent fashion and induce cell death within 48 hours.
MATERIALS AND METHODS
Materials and peptide preparation
α-Amanitin, 4′,6-diamidino-2-phenylindole (DAPI) and propidium iodine (PI) were
purchased from Sigma-Aldrich, N-succinimidyl 3-(2-pyridyl-dithio)-propionate (SPDP) and
sulfosuccinimidyl 6-[α-methyl-α-(2-pyridyldithio)toluamido]hexanoate (sulfo-Lc-SMPT),
N-[α-maleimidoacetoxy] succinimide ester (AMAS) were from Thermo Scientific, 6-
(fluorescein-5-carboxamido) hexanoic acid, succinimidyl ester (5-SFX) was from
Invitrogen, and anexinV-FITC was from BD Biosciences. The pHLIP peptides with single
Cys at the C- or N-terminus (pHLIP-Cys:
AEQNPIYWARYADWLFTTPLLLLDLALLVDADEGCT and Cys-pHLIP:
ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT) were synthesized and purified
by Dr. James I. Elliott at the W.M. Keck Foundation Biotechnology Resources Laboratory at
Yale University (New Haven, CT).
Conjugation of amanitin to pHLIP
First, amanitin was conjugated with a cross-linker (cleavable SPDP, sulfo-Lc-SMPT, or
non-cleavable, AMAS). Amanitin was incubated at room temperature for 4 hours with 10x
excess of crosslinker in 50 mM sodium phosphate buffer of pH 7.6 containing 150 mM
sodium chloride followed by purification of the products by reverse phase HPLC. Next,
Cys-pHLIP or pHLIP-Cys peptide was incubated with SPDP-amanitin or Lc-SMPT-
amanitin or AMAS-amanitin in 100 mM sodium phosphate buffer pH 7.8 (saturated with
argon) containing 150 mM sodium chloride at a ratio of 1:1 at room temperature for 1 hour.
The final products were purified by reverse phase HPLC, lyophilized and characterized by
SELDI-TOF mass-spectrometry. The concentration of constructs was determined by
absorbance of amanitin at 310 nm using molar extinction coefficient of 13,000 M−1 cm−1.
Synthesis of amanitin-SFX
Amanitin was incubated with 6-(fluorescein-5-carboxamido) hexanoic acid, succinimidyl
ester (SFX) in 50 mM sodium phosphate 150 mM sodium chloride buffer pH 7.6 at a ratio
1:5 at room temperature for 4 hours followed by purification of the product by reverse phase
HPLC and characterized by SELDI-TOF mass-spectrometry.
Measurements of water-octanol partition coefficient
polarity of amanitin and amanitin conjugated to the SPDP or Lc-SMPT crosslinkers were
determined by assessment of relative partitioning between aqueous and octanol liquid
phases. Constructs dissolved in MeOH:water 1:1 were added to 0.5 ml of 10 mM phosphate
buffer pH 7.4 (saturated with argon), followed by the addition of argon saturated n-octanol
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(0.5 ml) and sealed under argon. The solutions were mixed by rotation for 24 hours at room
temperature and left for another 24–48 hours for equilibration. After phase separation,
absorption at 300 nm was recorded. molar extinction coefficients in n-octanol and phosphate
buffer are assumed to be the same, and the ratio of the OD readings was used directly to
calculate the partition coefficient, P = ODn-octanol/ODwater, and Log P values.
Liposome preparations
Liposomes were prepared by extrusion: POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine) was transferred to a round bottom flask, and a lipid layer was obtained by
evaporating the choloroform in a rotary evaporator, followed by drying under high vacuum
for 2 hours. The lipid layer was resuspended in 10 mM phosphate buffer, pH 8, and extruded
31 times through a 100 nm membrane to obtain large unilamellar vesicles.
Steady-state fluorescence and circular dichroism measurements
Intrinsic peptide fluorescence and circular dichroism (CD) spectra were measured on a PC1
ISS spectrofluorometer (ISS, Inc.) and a MOS-450 spectrometer (Biologic, Inc.),
respectively. All measurements were performed at 25°C. Samples of 2 μM of pHLIP-SPDP-
Am and pHLIP-Lc-SMPT-Am incubated overnight in presence or absence of 2 mM POPC
in pH 8 phosphate buffer were used for the measurements of CD and fluorescence signals of
the states I and II. State I is the peptide in solution at pH 8; state II is the peptide in the
presence of POPC liposomes at pH 8; state III reflects folding and insertion of the peptide
into lipid bilayer of liposomes and formation of transmembrane helix, when pH is dropped
from 8 to 3.6 by addition of an aliquot of 0.1 M HCl. Peptide fluorescence spectra were
recorded from 310 nm to 400 nm using excitation wavelength of 280 nm. Peptide CD
spectra were recorded from 190 nm to 260 nm in 0.5 nm increments using a sample cuvette
with an optical path length of 0.5 cm.
pH-dependence
pH-dependent partitioning of pHLIP-SPDP-Am into lipid bilayer was investigated by the
shift of the position of the peptide intrinsic fluorescence spectral maximum for the pHLIP
induced by a drop of pH from 8 to 3 by the addition of HCl in the presence of POPC
liposomes. 2 μM of the peptide was incubated overnight with 2 mM of POPC liposomes,
and pH was decreased by the addition of aliquots of 0.1 M HCl. The resulting pHs were
measured using a micro-electrode probe (Thermo Electron Corporation, Orion Ross Micro
pH electrode). Fluorescence spectra were recorded at each pH value. The spectra were
analyzed with decomposition algorithms using an on-line PFAST toolkit (Protein
Fluorescence And Structural Toolkit: http://pfast.phys.uri.edu/ (23)) to obtain spectral
maxima (λmax). Finally, the positions of the fluorescence spectral maxima (λmax) of the
single component solutions were plotted versus pH, and the Henderson–Hasselbalch
equation was used to fit the data:
where λ1max and λ2max are fluorescence maximum wavelengths at the beginning and end of
the transition, respectively, and the pKa is the midpoint of the transition. It is assumed that
there is a linear relation between the position of the maximum and the contribution of state
II (or state III). However, due to the fact that quantum yields in states II and III are slightly
different, there was a slight non-linearity. According to our previous estimation the apparent
pK shifts no more than 0.05 pH units toward lower pHs if quantum yields of state II and III
are taken into account (24). Since this shift is less than the experimental error, we present
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the pKa values for transitions from the state II to III based on the analysis of the positions of
spectral maxima and assuming that quantum yield is the same in states II and III.
Cell lines
Human cervix adenocarcinoma (HeLa) cells, human osteosarcoma (U2OS) cells, human
breast ductal carcinoma M4A4 cells and human breast adenocarcinoma MDA-MB-231 cells
were acquired from the American Type Culture Collection. Human cervix adenocarcinoma
with stable expression of green fluorescent protein (GFP) HeLa-GFP cells was acquired
from the Cell Biolabs Inc. Cells were authenticated, stored according to the supplier’s
instructions, and used within 3 months after frozen aliquot resuscitations. Cells were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 10 μg/mL of ciprofloxacin in a humidified atmosphere of 5% CO2 and
95% air at 37°C. The pH 6.0 medium was prepared by mixing 13.3 g of dry DMEM in 1 L
of deionized water.
Fluorescence Microscopy
HeLa-GFP and HeLa cells were grown in 35-mm dishes with 14-mm glass-bottom windows
coated with collagen. Cells were transferred to DMEM of pH 6.5 or 7.4 followed by
incubation with 0.5–1 μM of pHLIP-S-S-amanitin at the same pHs for 2 hours. Control cells
were treated with 1 μM of staurosporine for 4 hours. After treatment construct was removed
and cells were transferred to the standard growth medium. At various time points cells were
stained with 5 μg/ml of DAPI or 2 μg/ml of PI for 20 min or Annexin V-FITC according to
the manufacturer’s instructions followed by intensive washing. Fluorescent and phase-
contrast images of the cells were acquired with a Retiga CCD camera (Q-imaging) mounted
onto the inverted Olympus IX71 microscope (Olympus America, Inc.). To monitor the
changes in cell morphology in real time after treatment with pHLIP-S-S-amanitin, dishes
with cells were placed in live cell imaging chamber (Tokai Hit).
Proliferation Assay
HeLa, U2OS, M4A4 or MDA-MB-231 cells were loaded in the wells of 96-well plates
(~5,000 cells per well) and incubated overnight. Growth medium was replaced with medium
without FBS at pH 6.0 or pH 7.4 containing increasing amounts of constructs (0.125, 0.25,
0.5 and 1 μM and up to 10 μM for amanitin and amanitin-SFX). In most cases treatment
was performed in DMEM of pH 6.0 and 7.4, while in case of pHLIP-Lc-SMPT-amanitin
treatment was performed in PBS pH 6.2 or 8.0. After 2 hours of treatment, the constructs
were removed and replaced with standard growth medium containing 10% FBS. Cell
viability was assessed by colorimetric reagent (CellTiter 96 AQueous One Solution Assay,
Promega), which was added for 1 hour to cells followed by measuring absorbance at 490
nm. All samples were prepared in triplicate. Each experiment was repeated at least 3 times.
ECIS Assay
The kinetics of inhibition of proliferation of HeLa-GFP cells treated with pHLIP-SPDP-Am
at pH 6.5 were monitored by changes of capacitance measured at AC frequencies on an
ECIS® 8Z (electric cell-substrate impedance sensing) instrument (Applied Biophysics, Inc.).
Cells (~5,000 cells per well) were loaded in 8W10E+ 8-well plate (Applied Biophysics Inc.)
and incubated overnight. Each well had two sets of 20 circular 250 μm diameter active gold
electrodes. Growth medium was replaced with the medium without FBS of pH 6.0 or pH 7.4
containing 0.5 μM of pHLIP-SPDP-amanitin or amanitin alone. The constructs were
removed after 2 hours of treatment, and the cells were incubated in standard growth medium
for 60 hours. Changes in capacitance were monitored for 50 hours after the treatment. The
time of the treatment was set as zero.
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RESULTS
Biophysical characterization of pHLIP-Amanitin interaction with membrane
A bi-cyclic peptide, amanitin, containing a reactive NH2 group was conjugated with the C-
terminus of pHLIP via a cleavable S-S bond by two cross-linkers of different polarity: long-
chain hydrophobic Lc-SMPT and short-chain, more polar SPDP (Figure 1a). The three states
of pHLIP-amanitin constructs were monitored by changes of peptide fluorescence excited at
280 nm (Figure 1b, d) and circular dichroism (Figure 1c, e) spectral signals. State I
represents the construct in aqueous solution at pH 8; addition of liposomes results in
transition to state II, where the pHLIP peptide is in equilibrium between membrane-bound
and free forms, and state III reflects insertion of the peptide into the lipid bilayer and
formation of a transmembrane helix as the result of pH drop from 8 to 4 (25). The non-
physiological pH values of 8 and 4 were selected to ensure the completion of transition in
this model experiment on liposomes. Both constructs show pH-dependent interaction with
the lipid bilayer of membrane. However, at pH 8 in the presence of liposomes (state II, blue
lines on Figure 1) the amount of membrane inserted form is higher for pHLIP-Lc-SMPT-
Am compared to pHLIP-SPDP-Am. This is reflected by a 3 nm shift of the position of
maximum of fluorescence spectrum to short wavelengths (λmax of pHLIP-SPDS-Am and
pHLIP-Lc-SMPT-Am in the state II is 347 and 344 nm, respectively), an 11% increase of
fluorescence signal and a decrease of molar ellipticity at 220 nm (Θ zof pHLIP-Lc-SMPT-
Am and pHLIP-Lc-SMPT-Am in the state II is 8.3×103 to 6.8×103, deg cm2 dmol−1). It
could be explained by the difference in hydrophobicity of the amanitin cargo conjugated to
the two different cross-linkers. Conjugation of the polar membrane-impermeable amanitin
(LogP is about −2, Figure 1f) to the cross-linkers reduces the polarity of the constructs
(LogP of amanitin-SPDP is about −0.2) and converts amanitin-Lc-SMPT cargo to slightly
membrane permeable (positive value of LogP=0.2), which results in the higher affinity of
pHLIP-Lc-SMPT-Am to the lipid bilayer of the membrane already at pH 8. The cell
experiments were mostly performed with pHLIP-SPDP-Am, which has an apparent pK of
insertion into the membrane equal to 5.9, similar to the pHLIP peptide alone and to the
pHLIP conjugated to phallatoxin and biotin cargoes (18, 24, 26).
Inhibition of cell proliferation
Amanitin is a potent inhibitor of RNA polymerase II, which, once translocated into cells,
induces their death. Amanitin is a polar molecule and cannot freely diffuse across the
membrane, especially at low concentrations. The ability of pHLIP to move amanitin across
the membrane and to inhibit cell proliferation in concentration- and pH-dependent manners
was evaluated on several cancer cell lines (Figure 2). Time of incubation of constructs with
cells was varied, and the cytotoxic effect was evaluated using standard MTS assay at various
time points. All data presented here were obtained at 2 hours of incubation of the constructs
with cells, followed by the removal of the constructs and transfer of the cells to standard cell
growth medium. Cell death was monitored at 48 hours after the treatment.
pH-Dependent inhibition of proliferation of HeLa cells treated with pHLIP-Lc-SMPT-Am
was observed only when treatment was performed in PBS of pH 8 (Figure 2a), since at
neutral pH cytotoxic effect was just slightly less compared to low pH treatment (data not
shown). At the same time, the cytotoxic effect of pHLIP-SPDP-Am was significantly lower
at pH 7.4, while at pH 6.0 concentration-dependent cell death was observed (Figure 2b).
Cells treated with amanitin conjugated to the N-terminus of pHLIP (Am-SPDP-pHLIP)
show slight toxicity at low pH at concentrations of 1 μM (Figure 2c), which might be
associated with partial endocytotic uptake of the construct by the cells promoted by
interaction of pHLIP with plasma membrane at low pH or the possibility of the insertion of
some population of the peptide into cellular membrane translocating the N-terminus across a
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bilayer. The cytotoxic effect after cells treatment with Am-SPDP-pHLIP was much lower
compared to the effect after treatment with pHLIP-SPDP-Am. Another control experiment
was performed with amanitin conjugated to the C-terminus of pHLIP via a non-cleavable
cross-linker, AMAS, of similar polarity as SPDP (pHLIP-AMAS-Am). No cellular toxicity
was observed at either pHs in a wide range of concentrations (Figure 2d), which confirms
that amanitin needs to be released from the peptide to diffuse to the nucleus and find its
target.
Treatment of various cancer cell lines including human osteosarcoma (U2OS), breast ductal
carcinoma (M4A4) and breast adenocarcinoma (MDA-MB-231) with pHLIP-SPDP-Am led
to the inhibition of cell proliferation in concentration- and pH-dependent manners (Figure
2e–g). All cells were also treated with amanitin alone and no toxicity was observed (data not
shown).
Besides the testing of the pHLIP-based constructs we evaluated the cytotoxic effect of
amanitin conjugated with fluorescein-hexanoic acid (SFX), which contains protonatable
carboxyl group and hexanoic acid for the enhancement of affinity of the construct to the
membrane. Some pH-dependent toxic effect was observed only at concentrations (10 μM)
10 times higher than what was needed for the inhibition of cell proliferation by pHLIP-
SPDP-Am (Figure 2h).
Kinetics of inhibition of cell proliferation
The kinetics of inhibition of proliferation of HeLa-GFP cells treated with pHLIP-SPDP-Am
at pH 6.5 was monitored by the changes in capacitance measured at AC frequencies using
ECIS (Figure 3a). Capacitance varies in a linear fashion with the fractional cell coverage of
the bottom of a special chamber coated with thin film gold electrodes connected to the ECIS
electronics (27). When cells are shrinking and dying after treatment with pHLIP-SPDP-Am
the capacitance increased, reaching saturation at 40–50 hours after the treatment. Changes in
cell morphology were also observed on the optical microscope connected to the live-cell
chamber (Figure 3b–f). In accordance to the capacitance measurements, the changes in cell
morphology (rounding of the cells) were completed at 49 h.
Mechanism of cell death
To evaluate the mechanism of cell death induced by pHLIP-SPDP-Am we monitored the
appearance of phosphatidylserine on the outer surface of the plasma membrane and the
DNA fragmentation, which are signs of early apoptosis. Non-treated HeLa cells and cells
treated with pHLIP-SPDP-Am and staurosporine, which is known to induce apoptosis in
HeLa cells (28, 29), were stained with cell-impermeable phosphatidylserine-binding protein,
AnnexinV-FITC. The plasma membrane of cells at 4 hours after the treatment with
staurosporine was stained with AnnexinV-FITC (Figure 4e), while the integrity of
membrane was not compromised in most cases, since cell-impermeable DNA-staining dye,
PI, was not able to label cellular nucleus (Figure 4f). Despite the fact that at 11 hours after
the treatment with pHLIP-SPDP-Am some cells already underwent morphological changes
(Figure 4a), we did not observe appearance of the phosphatidylserine on the outer leaflet of
plasma membrane. Another sign of early apoptosis, DNA fragmentation, was evaluated on
HeLa cells at various time points (5, 8, 11, 14 and 17 h) after treatment with pHLIP-SPDP-
Am by staining the cells with the membrane-impermeable DNA-binding dye, DAPI. The
cells at selected time points after the treatment are shown on Figure 4j-o. With progression
in time, the number of cells with changed morphology (Figure 4j, l, n, shown by asterisk)
was increasing, while the DNA fragmentation was occurring only in a small population
(Figure 4k, m, o, shown by arrows). We concluded that the major pathway of cell death after
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pHLIP-SPDP-Am treatment is necrotic; however we cannot exclude that apoptotic pathway
could also be triggered in some subset of cells.
DISCUSSION
α-Amanitin belongs to the class of strong toxins and can induce cell death within 48 hours.
However, it is too polar to cross cellular membrane by itself, except that of liver cells, which
have a special transporting system for the uptake of small cyclic molecules like phallo- and
amanita toxins (30). Amanitin could be considered as a potent anti-cancer drug if it can be
delivered only to cancer cells and translocated across the membrane. Recently the anti-
proliferative effect of α-amanitin conjugated with anti-EpCAM antibody was tested on
human cancer cell lines and assessed in vivo in immune-compromised mice bearing
subcutaneous human pancreatic carcinoma xenograft tumors (31). The study suggested that
anti-EpCAM antibody conjugates with α-amanitin have the potential to be highly effective
therapeutic agents for pancreatic carcinomas and various EpCAM-expressing malignancies.
Here we tested the capability of novel pHLIP-based drug delivery system to translocate α-
amanitin across the membrane into the cytoplasm. This system is based on a pH-dependent
spontaneous insertion and folding of pHLIP peptide in the membrane. The molecular
mechanism of pHLIPs action is a protonation of Asp/Glu residues in mildly acidic
environment, which leads to the increase of hydrophobicity of the peptide and promotes
peptide insertion and folding in the membrane. It is important to outline that in contrast to
normal cells, cancer cells have a negative transmembrane pH gradient (extracellular pHe is
lower than intracellular pHi), which promotes accumulation of weak acids in cancer cells
(32, 33). Thus, in cancer cells the equilibrium is shifted toward pHLIP inserted form, since
Asp and Glu residues at the C-terminus of the peptide are de-protonated in cytoplasm in the
environment of higher pHi. The energy of membrane-associated folding (about 2 kcal/mol)
could be used to move polar cell-impermeable cargo molecules across lipid bilayer of
membrane (8, 17, 18, 26). Our data indicate that the translocation capability could be tuned
by conjugating amanitin to the C-terminus of pHLIP via more or less hydrophobic linkers.
We found that pHLIP-SPDP-amanitin exhibits the most favorable properties demonstrating
4–5 times higher anti-proliferative ability at pH 6 compared to pH 7.4. The major
mechanism of amanitin delivery is direct translocation across membrane by pHLIP and
cleavage of the S-S bond in the cytoplasm. Amanitin conjugated to pHLIP via a non-
cleavable cross-linker was not able to induce cell death. Anti-proliferative effect was
observed on four different human cancer cell lines. Most cells undergo necrosis, and cell
death was observed at 40–50 hours after treatment. The cytotoxic effect was achieved as the
result of cell treatment for 2 hours with the pHLIP-amanitin construct at concentrations of
0.25–1 μM. It could be very favorable for in vivo delivery, where the blood flow is
significant and small therapeutic molecules have limited time for the accumulation in
tumors. We already demonstrated that pHLIP targets acidic solid tumors of various origins
with high accuracy and stains entire tumor mass to the degree that correlates with
extracellular acidity (10–12, 14, 34). Therefore, pHLIP might be effective in the delivery of
phallo- and amanita-toxins to tumors and in their translocation across the membrane of
cancer cells with low extracellular pH and reverse pH gradient. Amanitin will be most
effective in killing highly-proliferative cancer cells, which actively synthesize proteins.
Thus, selective death of cancer cells with minimal effect on normal cells might be achieved
using pHLIP-mediated delivery of phallo- and amanita toxins.
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ABBREVIATIONS
AC alternating
Am amanitin
AMAS N-[α-maleimidoacetoxy] succinimide ester
CCD charged coupled device
CD circular dichroism
DAPI 4′,6-diamidino-2-phenylindole
DMEM Dulbecco’s Modified Eagle’s medium
ECIS electric cell-substrate impedance sensing
EpCAM epithelial cell adhesion molecule
FBS fetal bovine serum
FITC fluorescein isothiocyanate
HPLC high liquid pressure chromatography
OD optical density
PET positron emission tomography
PFAST protein fluorescence and structural database
pHLIP pH Low Insertion Peptide
PI propidium iodide
POPC 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
SELDI-TOF surface enhanced laser desorption ionization time-of-flight
SFX 6-(fluorescein-5-carboxamido) hexanoic acid, succinimidyl ester
SPDP N-succinimidyl 3-(2-pyridyl-dithio)-propionate
SPECT single photon emission tomography
sulfo-Lc-SMPT succinimidyl 6-[α-methyl-α-(2-pyridyldithio)toluamido]hexanoate
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Figure 1. Interaction of pHLIP-amanitin with lipid bilayer of liposomes
a) Chemical structure of amanitin, long-chain (Lc-SMPT) and short-chain (SPDP) cross-
linkers. Fluorescence (b, d) and CD (c, e) spectra representing three states of pHLIP-
amanitin conjugated via long-chain, SMPT, (b, c) and short-chain, SPDP, (d, e) cross-linkers
are shown. State I corresponds to the construct in aqueous solution at pH 8, addition of
liposomes results in formation of state II, and state III represents peptide inserted into lipid
bilayer at pH 4. f) LogP values of amanitin and its conjugates with long- and short-chain
cross-linkers are shown (where P is the octanol-water partition coefficient). d) The pH-
dependence of pHLIP-SPDP-Am transition from the state II to the state III is shown.
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Figure 2. Inhibition of cell proliferation
Human cervix adenocarcinoma, HeLa-GFP (a–d, h) human osteosarcoma, U2OS (e), human
breast ductal carcinoma M4A4 (f) and human breast adenocarcinoma MDA-MB-231 (g)
were treated with the following constructs: pHLIP-Lc-SMPT-Am (a), pHLIP-SPDP-Am (b,
e–g), Am-SPDP-pHLIP (c), pHLIP-AMAS-AM (d), amanitin-SFX and amanitin alone (h)
for 2 hours in DMEM of normal/high pH (light and dark gray columns) or low pH (pH 6.2 –
blue column and pH 6.0 – red and magenta columns) followed by the removal of the
constructs and the transfer of cells to standard cell growth medium, MTS assay was
performed at 48 hours after the treatment. Amanitin and pHLIP alone have no effect on
proliferation of all investigated cell lines at both pHs (data not shown).
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Figure 3. Time course of inhibition of cell proliferation
HeLa-GFP cells were treated with pHLIP-SPDP-Am for 2 hours in DMEM at pH 6.5
followed by the removal of the construct (zero time point) and the transfer of cells to the
standard growth medium. The kinetics of inhibition of cell proliferation were monitored by
changes of capacitance (a) and cell morphology (b–f).
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Figure 4. The pathway of cell death
Non-treated HeLa cells (g–i) and cells treated with pHLIP-SPDP-Am (a–c) at 11 h after
treatment, and with staurosporine (d–f) at 4 h after treatment were stained with AnexinV-
FITC to monitor the appearance of phosphatidylserine at the outer surface of the plasma
membrane (b, e, h) and PI (c, f, i). The changes in cell morphology (j, l, n) and DNA
fragmentation monitored by staining cell nuclear with DAPI (k, m, o) of HeLa cells treated
with pHLIP-SPDP-Am were observed at 5, 11 and 17 hours after the treatment. Only in a
small population of cells, which show changes in cell morphology (shown by asterisk), the
DNA fragmentation was observed (shown by arrows).
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